Sol and Clara Kest Professor
Chairman, Department of Dermatology
Mount Sinai School of Medicine
New York, New York
Of note: Past President, New York Dermatological Society; Past President, Manhattan Dermatologic Society; Past President, New York State Society of Dermatology; Past Chair, Dermatology Section of the New York Academy of Medicine; Past Chair, Psoriasis Task Force of the American Academy of Dermatology; Chair of the American Academy of Dermatology meeting in Washington, DC, 2004; member of the Board of Directors of the American Academy of Dermatology 2010–2014; current Chair of the Medical Board of the National Psoriasis Foundation; Founding Editor, Psoriasis Forum; Medical Editor, the bulletin of the National Psoriasis Foundation, Psoriasis Advance; editorial board member of the Journal of the American Academy of Dermatology; Editor or Author, Difficult Diagnoses in Dermatology, Psoriasis, The Skin and Systemic Disease, Mild-to-Moderate Psoriasis and Moderate-to-Severe Psoriasis, and Treatment of Skin Disease.
Special interests: New dermatologic treatment options, including those for psoriasis.
Financial Disclosure: Consultant for Abbott Laboratories, Anacor Pharmaceuticals, BioLineRX, Galenica Pharmaceuticals, Genentech, Maruho, Meda Pharmaceuticals, Pfizer, Taro Pharmaceuticals, UCB Pharma, and Valeant Pharmaceuticals. He is an investigator for AbGenomics, Clinuvel, GlaxoSmithKline-Stiefel, Inbios, and Janssen Biotech and is a consultant and investigator for Amgen, Can-Fite Biopharma, Celgene Corporation, Coronado Biosciences, Eli Lilly, LEO Pharmaceuticals, Merck Pharmaceuticals, Merz Pharmaceuticals, Novartis, and Ranbaxy Laboratories. He is also a consultant and stock shareholder at Dermipsor. The editor also received honoraria, which were donated directly to charity, from Galderma. Members of Dr. Lebwohl's department own patents on short-contact tazarotene, topical genistein, and use of the excimer laser for vitiligo. Members of Dr. Lebwohl's Department serve as investigators for numerous companies including: Abbott, Actavis, Amgen, aRigen, Astellas, Basilea, Bayer/Intendis, Bioform, Can-Fite Biopharma, Celgene, Centocor, DUSA, Eli Lilly, Ferndale, Fougera Pharmaceuticals, Galderma, Genentech, Graceway, Lumenis, Medicis, Merck/Schering Plough, Merz, Novartis, Nycomed, Onset Therapeutics, Peplin, Pfizer, Provectus, Ranbaxy, Regeneron, Stiefel, Valeant, Vascular Biogenics, and Wyeth. Dr. Lebwohl is a course director for the annual Fall and Winter Clinical Dermatology Conferences, The Real World Dermatology for Residents Conference sponsored by the National Society for Cutaneous Medicine, and the annual Mount Sinai Winter Symposium which receive support from numerous dermatology companies.